[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation

Trial details

Who runs it

John O. Prior

Trial code

NCT05499637

Record updated

13 October 2026

Original description

Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and the immune checkpoint inhibitor induced myocarditis (ICIM), for which non-invasive diagnosis remains challenging.Read full original descriptionShow less

Pilot Study to Evaluate the Accuracy of [68Ga]Ga-PentixaFor PET/CT in the Diagnosis of Three Clinical Entities of Acute Myocardial Inflammation

Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute cellular cardiac allograft rejection (ACR), cardiac sarcoidosis (CS) and the immune checkpoint inhibitor induced myocarditis (ICIM), for which non-invasive diagnosis remains challenging.

Since accurate diagnosis of myocardial inflammation in an early stage is crucial, this study aims to investigate the accuracy of [68Ga]Ga-PentixaFor as a marker of for the presence of inflammatory cells (T-lymphocytes and M1) in described patients.

The identification of a correlation between [68Ga]Ga-PentixaFor myocardial accumulation with currently accepted diagnostic tools would open up new ways to non-invasively diagnose acute myocardial inflammation.

Inclusion: signed written informed consent; male or female; age ≥ 18 years; patients with suspicion CS (group II) or ICIM (group III) or in their regular follow-up in their first year after HT (group I); SOC clinical follow-up at the cardiology department in CHUV.

Exclusion: previous enrolment into the current study; myocardial ischemia in non-invasive perfusion test or coronarography in group II and III; clinically unstable cardiovascular conditions, including:; clinically unstable brady-tachyarrhythmia; severe and symptomatic hypo- or hypertension with documented systolic blood pressure < 90 mmHg or ≥220 mmHg respectively; cardiogenic shock; history of any disease or relevant physical or psychiatric condition or abnormal physical finding which may interfere with the study objectives at the investigator judgment; moderate to severe renal insufficiency (GFR < 45 mL/min/1,73 m2), with contra-indication to the administration of Gadolinium in group II and III; patients aged < 18 years; The presence of any one of the following exclusion criteria will lead to exclusion of the participant:; absence of a signed written informed consent; claustrophobia; women who are pregnant or breast feeding; intention to become pregnant during the course of the study in group II; enrollment of the investigator, his/her family members, employees and other dependent persons; insufficient knowledge of project language, inability to give consent or to follow procedures; the patient makes use of his/her "right not to know" and refuses to be informed about incidental findings.

ClinicalTrials.gov NCT05499637